2023
Plasmapheresis Versus Intravenous Immunoglobulin in Patients With Autoimmune Neuromuscular and Neuro-immunological Conditions
Zubair A, Rethana M, Ma A, McAlpine L, Abulaban A, Munro B, Patwa H, Nowak R, Roy B. Plasmapheresis Versus Intravenous Immunoglobulin in Patients With Autoimmune Neuromuscular and Neuro-immunological Conditions. Journal Of Clinical Neuromuscular Disease 2023, 25: 11-17. PMID: 37611265, DOI: 10.1097/cnd.0000000000000439.Peer-Reviewed Original ResearchConceptsNeuro-immunological diseaseIntravenous immunoglobulinAutoimmune neurological disordersAutoimmune neuromuscular disorderAdult patientsElderly patientsNeurological disordersNeuromuscular disordersChronic inflammatory demyelinating polyradiculoneuropathyNational Inpatient Sample databaseNational Inpatient Sample datasetInflammatory demyelinating polyradiculoneuropathySafe therapeutic choiceRetrospective chart reviewAppropriate clinical settingSide effect profileDemyelinating polyradiculoneuropathyIVIG useChart reviewYounger patientsMyasthenia gravisEffect profileMedical historyPrimary diagnosisTherapeutic choice
2020
Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: A network meta-analysis
Das A, Mahapatra S, Bandyopadhyay D, Samanta S, Chakraborty S, Philpotts LL, Jahangir E, Roy B. Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: A network meta-analysis. Critical Reviews In Oncology/Hematology 2020, 157: 103186. PMID: 33309571, DOI: 10.1016/j.critrevonc.2020.103186.Peer-Reviewed Original ResearchConceptsTyrosine kinase inhibitorsHemorrhagic eventsVEGFR-TKICancer patientsOdds ratioVascular endothelial growth factor tyrosine kinase inhibitorVascular endothelial growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsReceptor tyrosine kinase inhibitorsKinase inhibitorsHigh-grade bleedingSide effect profileStandard chemotherapeutic regimenFirst-choice treatmentConfidence intervalsRandom-effects modelTypes of cancerVEGFR-TKIsChemotherapeutic regimenPrimary outcomeClinical trialsHigh riskPlaceboComparative riskPatients